Advertisement

Japanese Journal of Ophthalmology

, Volume 57, Issue 1, pp 104–107 | Cite as

Treatment of recurrent anterior uveitis with infliximab in patient with ankylosing spondylitis

  • Junko MatsudaEmail author
  • Toshikatsu Kaburaki
  • Shigeto Kobayashi
  • Jiro Numaga
Clinical Investigation

Abstract

Background

We describe a HLA-B27-positive Japanese man with recurrent severe anterior uveitis OU and ankylosing spondylitis (AS) who was successfully treated with infliximab.

Case

A 25-year-old HLA-B27-positive Japanese man presented with recurrent anterior uveitis OU. The symptoms were consistent with typical HLA-B27-associated uveitis, whereas the subsequent course, which consisted of frequent episodes of recurrent severe anterior uveitis, was atypical. Although the patient was treated with intensive topical corticosteroids, cycloplegic treatment, sub-Tenon triamcinolone acetonide injections, systemic corticosteroids and immunosuppressive agents, recurrence of the anterior uveitis persisted. Over 8 years there were 14 documented episodes of recurrent anterior uveitis OD and 10 OSs. At age 33, the patient was diagnosed with AS after a radiographic examination. We began infusions of infliximab (2.5 mg/kg) at 0, 2 and 6 weeks, and then every 8 weeks thereafter. The recurrent uveitis disappeared, and the immunosuppressive agents and oral corticosteroids were tapered and discontinued without relapse. All drugs other than infliximab were successfully stopped in October 2010. During the follow-up period, there were no adverse events.

Conclusion

A case of severe recurrent anterior uveitis OU in a patient with AS with infliximab was successfully treated. This is the first report describing the efficacy of infliximab in AS-associated uveitis in Japan.

Keywords

Ankylosing spondylitis Anterior uveitis Hla-B27 Infliximab Tumor necrosis factor inhibitor 

References

  1. 1.
    van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Chang JH, McCluskey PJ, Wakefield D. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 2005;50:364–88.PubMedCrossRefGoogle Scholar
  3. 3.
    Wakefield D, Montanaro A, McCluskey P. Acute anterior uveitis and HLA-B27. Surv Ophthalmol. 1991;36:223–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol. 1997;81:1107–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye. 2000;14:340–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696–701.PubMedCrossRefGoogle Scholar
  7. 7.
    El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002;109:2342–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.PubMedGoogle Scholar
  10. 10.
    Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52:2447–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology. 2006;113:2317–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha. monoclonal antibody infliximab. Arthritis Rheum. 2000;43:1346–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Papadia M, Herbort CP. Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis. Ocul Immunol Inflamm. 2010;18:482–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Wilkinson M, Bywasters EG. Clinical features and course of ankylosing spondylitis; as seen in a follow-up of 222 hospital referred cases. Ann Rheum Dis. 1958;17:209–28.PubMedCrossRefGoogle Scholar
  16. 16.
    Linssen A, Meenken C. Outcomes of HLA-B27-positive and HLA-B27-negative acute anterior uveitis. Am J Ophthalmol. 1995;120:351–61.PubMedGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2012

Authors and Affiliations

  • Junko Matsuda
    • 1
    Email author
  • Toshikatsu Kaburaki
    • 2
  • Shigeto Kobayashi
    • 3
  • Jiro Numaga
    • 1
  1. 1.Department of OphthalmologyTokyo Metropolitan Geriatric HospitalTokyoJapan
  2. 2.Department of OphthalmologyThe University of Tokyo Graduate School of MedicineTokyoJapan
  3. 3.Department of RheumatologyJuntendo University, Koshigaya HospitalSaitamaJapan

Personalised recommendations